Back to top
more

Guardant Health (GH)

(Delayed Data from NSDQ)

$21.40 USD

21.40
1,388,530

+0.79 (3.83%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $21.38 -0.02 (-0.09%) 7:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

What's in Store for Quest Diagnostics (DGX) in Q4 Earnings?

In Q4, Quest Diagnostics' (DGX) non-COVID base business might have registered a year-over-year sales rebound.

What's in Store for Boston Scientific's (BSX) Q4 Earnings?

On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.

After Plunging 27.6% in 4 Weeks, Here's Why the Trend Might Reverse for Guardant Health (GH)

Guardant Health (GH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -17.78% and 2.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Guardant Health (GH)

Guardant Health (GH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -10.34% and 8.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Kevin Cook headshot

Bear of the Day: NeoGenomics (NEO)

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

Earnings Preview: Guardant Health (GH) Q2 Earnings Expected to Decline

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bull of the Day: Exact Sciences (EXAS)

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

New Strong Sell Stocks for July 7th

ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.

J&J's (JNJ) Amivantamab Gets FDA Nod for Rare Lung Cancer

With the FDA nod, J&J's (JNJ) Rybrevant becomes the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC that targets EGFR exon 20 insertion mutations.

Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of 40.24% and 5.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

Bear of the Day: Guardant Health (GH)

Cancer detection innovator with liquid biopsy saw analysts slash estimates as R&D investment costs rise

New Strong Sell Stocks for March 29th

HTHT, FNLPF, GMRE, THRY, and GH have been added to the Zacks Rank #5 (Strong Sell) List on March 29, 2021

New Strong Sell Stocks for March 1st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -129.41% and 12.18%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kevin Cook headshot

7 Diagnostic and Genomic Stocks Storming Into October

COVID-19 has created an Apollo Mission status for advanced medical technologies and smart investors are profiting.

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Guardant Health (GH) to Report a Decline in Earnings: What to Look Out for

Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

Is (GH) Outperforming Other Medical Stocks This Year?

Will Guardant Health Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Guardant Health